The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC).
N. Harbeck
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
M. Kaufmann
No relevant relationships to disclose
F. Siedentopf
Honoraria - Roche
P. Dalivoust
No relevant relationships to disclose
M. Debled
No relevant relationships to disclose
N. J. Robert
Consultant or Advisory Role - Pfizer; Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Pfizer
J. O'Shaughnessy
Consultant or Advisory Role - Roche
Honoraria - Roche